IL238499B - A multivalent disulfide-linked type I Mhc containing multi-functional proteins - Google Patents
A multivalent disulfide-linked type I Mhc containing multi-functional proteinsInfo
- Publication number
- IL238499B IL238499B IL238499A IL23849915A IL238499B IL 238499 B IL238499 B IL 238499B IL 238499 A IL238499 A IL 238499A IL 23849915 A IL23849915 A IL 23849915A IL 238499 B IL238499 B IL 238499B
- Authority
- IL
- Israel
- Prior art keywords
- disulfide
- mhc class
- function proteins
- linked multivalent
- multivalent mhc
- Prior art date
Links
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12198904 | 2012-12-21 | ||
| EP13175469 | 2013-07-08 | ||
| PCT/EP2013/077109 WO2014096015A1 (en) | 2012-12-21 | 2013-12-18 | Disulfide-linked multivalent mhc class i comprising multi-function proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL238499A0 IL238499A0 (en) | 2015-06-30 |
| IL238499B true IL238499B (en) | 2018-10-31 |
Family
ID=49779923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238499A IL238499B (en) | 2012-12-21 | 2015-04-28 | A multivalent disulfide-linked type I Mhc containing multi-functional proteins |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10501521B2 (enExample) |
| EP (1) | EP2935328B1 (enExample) |
| JP (1) | JP6475167B2 (enExample) |
| KR (1) | KR20150097688A (enExample) |
| CN (1) | CN104884474A (enExample) |
| AR (1) | AR094149A1 (enExample) |
| AU (1) | AU2013360775B2 (enExample) |
| CA (1) | CA2889788A1 (enExample) |
| ES (1) | ES2700984T3 (enExample) |
| HK (1) | HK1214276A1 (enExample) |
| IL (1) | IL238499B (enExample) |
| MX (1) | MX361076B (enExample) |
| PL (1) | PL2935328T3 (enExample) |
| RU (1) | RU2015129640A (enExample) |
| SG (1) | SG11201504414UA (enExample) |
| WO (1) | WO2014096015A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| US10988516B2 (en) | 2012-03-26 | 2021-04-27 | Uti Limited Partnership | Methods and compositions for treating inflammation |
| US9603948B2 (en) | 2012-10-11 | 2017-03-28 | Uti Limited Partnership | Methods and compositions for treating multiple sclerosis and related disorders |
| EP2925780B1 (en) * | 2012-11-30 | 2017-10-18 | Roche Glycart AG | Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins |
| AU2013360775B2 (en) | 2012-12-21 | 2018-04-12 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent MHC class I comprising multi-function proteins |
| RU2696876C2 (ru) | 2013-11-04 | 2019-08-07 | Ютиай Лимитед Партнершип | Способы и композиции для устойчивой иммунотерапии |
| ES2727552T3 (es) * | 2015-02-18 | 2019-10-17 | Hoffmann La Roche | Inmunoconjugados para la inducción específica de la citotoxicidad de los linfocitos T frente a una célula diana |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
| KR20190019068A (ko) | 2016-05-18 | 2019-02-26 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| MX2019005497A (es) | 2016-11-09 | 2019-11-18 | Uti Lp | Moleculas de pmhc de clase ii recombinantes. |
| US20190352363A1 (en) * | 2016-12-22 | 2019-11-21 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| US20200010528A1 (en) | 2017-03-15 | 2020-01-09 | Cue Biopharma, Inc. | Methods for modulating an immune response |
| AU2018374569B2 (en) | 2017-11-29 | 2024-10-17 | Uti Limited Partnership | Methods of treating autoimmune disease |
| CN111886241A (zh) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | 多聚体t细胞调节多肽及其使用方法 |
| EP3810188A1 (en) * | 2018-06-20 | 2021-04-28 | Danmarks Tekniske Universitet | Scaffolds with stabilized mhc molecules for immune-cell manipulation |
| US20220047710A1 (en) * | 2018-09-12 | 2022-02-17 | Washington University | Single chain constructs |
| DE102018122546B3 (de) * | 2018-09-14 | 2019-12-05 | Immatics Biotechnologies Gmbh | Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden |
| US20220073630A1 (en) * | 2018-12-28 | 2022-03-10 | Hoffmann-La Roche, Inc. | A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response |
| US11346844B2 (en) | 2019-04-26 | 2022-05-31 | Protein Metrics Inc. | Intact mass reconstruction from peptide level data and facilitated comparison with experimental intact observation |
| KR20220015382A (ko) * | 2019-05-29 | 2022-02-08 | 큐 바이오파마, 인크. | 다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법 |
| MX2022008533A (es) * | 2020-01-10 | 2022-08-08 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de la distrofia miotonica. |
| US20230212259A1 (en) * | 2020-02-21 | 2023-07-06 | 3T Biosciences, Inc. | Yeast display libraries, associated compositions, and associate methods of use |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| CN116437952A (zh) * | 2020-07-14 | 2023-07-14 | 库尔生物制药有限公司 | 具有缀合位点的t细胞调节多肽及其使用方法 |
| WO2022056014A1 (en) | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof |
| EP4303231A4 (en) * | 2021-02-07 | 2025-02-26 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BISPECIFIC ANTIBODY |
| US20240376464A1 (en) * | 2021-08-20 | 2024-11-14 | 3T Biosciences, Inc. | PEPTIDE-HLA-B*35 Libraries, Associated Compositions, and Associated Methods of Use |
| CN115838432B (zh) * | 2022-07-08 | 2023-12-08 | 浙江大学 | 一种靶向调控抗原特异性t细胞的融合蛋白及应用 |
| WO2025113640A1 (zh) * | 2023-11-30 | 2025-06-05 | 南京维立志博生物科技股份有限公司 | 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| DE3825615A1 (de) | 1988-07-28 | 1990-02-01 | Behringwerke Ag | Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung |
| US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
| DE68928994T2 (de) | 1988-11-03 | 1999-12-16 | Igen International, Inc. | Elektrochemilumineszente testverfahren |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| JPH03240498A (ja) | 1990-02-16 | 1991-10-25 | Nobuyoshi Shimizu | 抗体およびそれを使用した免疫分析方法 |
| IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6268411B1 (en) | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| WO1999007727A1 (en) * | 1997-08-12 | 1999-02-18 | Massachusetts Institute Of Technology | Eukaryotic disulfide bond-forming proteins and related molecules and methods |
| CA2307166A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US7521197B2 (en) | 1998-06-05 | 2009-04-21 | Alexis Biotech Limited | Method for producing cytotoxic T-cells |
| DE69930630T2 (de) | 1998-06-10 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | B2-Mikroglobulin-Fusionsproteine und Varianten mit hoher Affinität |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| JP2003530836A (ja) | 2000-04-12 | 2003-10-21 | ユニバーシティー オブ ロチェスター | 標的化ワクチン送達システム |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| GB0103998D0 (en) | 2001-02-19 | 2001-04-04 | King S College London | Method |
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| KR20100018071A (ko) | 2001-08-03 | 2010-02-16 | 글리카트 바이오테크놀로지 아게 | 항체 의존적 세포 독성이 증가된 항체 글리코실화 변이체 |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| JPWO2003085118A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物の製造方法 |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| JPWO2003085107A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | ゲノムが改変された細胞 |
| EP1502603A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM |
| EP1500698B1 (en) | 2002-04-09 | 2011-03-30 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in gdp-fucose transport |
| US20030199024A1 (en) | 2002-04-19 | 2003-10-23 | Hansen Ted H. | Single chain trimers of class I MHC molecules |
| US8895020B2 (en) | 2002-04-19 | 2014-11-25 | Washington University | Single chain trimers and uses therefor |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PL212899B1 (pl) | 2002-12-16 | 2012-12-31 | Genentech Inc | Humanizowane przeciwcialo, kompozycja zawierajaca to przeciwcialo, wyrób fabryczny, przeciwcialo lub jego fragment do zastosowania w sposobie indukowania apoptozy, izolowany kwas nukleinowy, wektor ekspresji, komórka gospodarza, sposób wytwarzania przeciwciala lub jego fragmentu, plynny preparat i zastosowanie przeciwciala do wytwarzania leku |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| ATE549359T1 (de) | 2003-04-02 | 2012-03-15 | Hoffmann La Roche | Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen |
| WO2005099361A2 (en) * | 2003-07-10 | 2005-10-27 | Vaccinex, Inc. | MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN |
| CA2542046A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Fused protein composition |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| RS54450B1 (sr) | 2003-11-05 | 2016-06-30 | Roche Glycart Ag | Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| EP2067789A1 (en) | 2004-04-13 | 2009-06-10 | F. Hoffmann-La Roche Ag | Anti-P selectin antibodies |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007025554A1 (en) | 2005-08-29 | 2007-03-08 | Medizinische Hochschule Hannover | Method for the generation of antigen-specific t-cells and uses thereof |
| US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2652538C (en) | 2006-05-19 | 2016-06-28 | Teva Pharmaceutical Industries, Ltd. | Fusion proteins, uses thereof and processes for producing same |
| US20080138354A1 (en) * | 2006-07-21 | 2008-06-12 | City Of Hope | Cytomegalovirus vaccine |
| US8992937B2 (en) | 2006-08-28 | 2015-03-31 | Washington University | Disulfide trap MHC class I molecules and uses therefor |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| WO2009039854A2 (en) * | 2007-09-27 | 2009-04-02 | Dako Denmark A/S | Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics |
| RU2379055C1 (ru) | 2008-04-30 | 2010-01-20 | Виктор Владимирович Кешелава | Способ лечения онкологических заболеваний |
| HUE029139T2 (hu) | 2011-02-10 | 2017-02-28 | Roche Glycart Ag | Mutáns interleukin-2 polipeptidek |
| EA201400046A1 (ru) * | 2011-06-22 | 2014-07-30 | Ф. Хоффманн-Ля Рош Аг | Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов |
| AU2013360775B2 (en) | 2012-12-21 | 2018-04-12 | F. Hoffmann-La Roche Ag | Disulfide-linked multivalent MHC class I comprising multi-function proteins |
| US12011480B2 (en) | 2015-05-06 | 2024-06-18 | Uti Limited Partnership | Nanoparticle compositions for sustained therapy |
-
2013
- 2013-12-18 AU AU2013360775A patent/AU2013360775B2/en not_active Ceased
- 2013-12-18 JP JP2015548483A patent/JP6475167B2/ja not_active Expired - Fee Related
- 2013-12-18 US US14/745,170 patent/US10501521B2/en not_active Expired - Fee Related
- 2013-12-18 MX MX2015007239A patent/MX361076B/es active IP Right Grant
- 2013-12-18 CA CA2889788A patent/CA2889788A1/en not_active Abandoned
- 2013-12-18 WO PCT/EP2013/077109 patent/WO2014096015A1/en not_active Ceased
- 2013-12-18 EP EP13808036.1A patent/EP2935328B1/en not_active Not-in-force
- 2013-12-18 HK HK16102155.9A patent/HK1214276A1/zh unknown
- 2013-12-18 KR KR1020157019208A patent/KR20150097688A/ko not_active Ceased
- 2013-12-18 CN CN201380066835.0A patent/CN104884474A/zh active Pending
- 2013-12-18 SG SG11201504414UA patent/SG11201504414UA/en unknown
- 2013-12-18 RU RU2015129640A patent/RU2015129640A/ru not_active Application Discontinuation
- 2013-12-18 ES ES13808036T patent/ES2700984T3/es active Active
- 2013-12-18 PL PL13808036T patent/PL2935328T3/pl unknown
- 2013-12-19 AR ARP130104873A patent/AR094149A1/es unknown
-
2015
- 2015-04-28 IL IL238499A patent/IL238499B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| EP2935328A1 (en) | 2015-10-28 |
| RU2015129640A (ru) | 2017-01-26 |
| AR094149A1 (es) | 2015-07-15 |
| CN104884474A (zh) | 2015-09-02 |
| KR20150097688A (ko) | 2015-08-26 |
| ES2700984T3 (es) | 2019-02-20 |
| CA2889788A1 (en) | 2014-06-26 |
| US20150344586A1 (en) | 2015-12-03 |
| JP2016501900A (ja) | 2016-01-21 |
| AU2013360775B2 (en) | 2018-04-12 |
| JP6475167B2 (ja) | 2019-02-27 |
| WO2014096015A1 (en) | 2014-06-26 |
| IL238499A0 (en) | 2015-06-30 |
| EP2935328B1 (en) | 2018-10-10 |
| MX361076B (es) | 2018-11-27 |
| SG11201504414UA (en) | 2015-07-30 |
| HK1214276A1 (zh) | 2016-07-22 |
| PL2935328T3 (pl) | 2019-02-28 |
| US10501521B2 (en) | 2019-12-10 |
| MX2015007239A (es) | 2015-08-12 |
| AU2013360775A1 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238499B (en) | A multivalent disulfide-linked type I Mhc containing multi-functional proteins | |
| IL235890A0 (en) | vaccine | |
| SG11201400432VA (en) | Polypeptide vaccine | |
| IL238221A0 (en) | self-injector | |
| PL2647387T3 (pl) | Kompozycja szczepionki | |
| GB201223386D0 (en) | Vaccine | |
| IL231043A (en) | vaccine | |
| GB201213117D0 (en) | Transgene expression | |
| IL236380A0 (en) | Temperature stable vaccine formulations | |
| GB201119999D0 (en) | Vaccine | |
| ZA201306245B (en) | Combination vaccines | |
| GB201013006D0 (en) | Vaccine | |
| GB201006324D0 (en) | Vaccine | |
| GB201210226D0 (en) | Vaccine | |
| GB201202090D0 (en) | Vaccine | |
| GB201120000D0 (en) | Vaccine | |
| DK2846829T3 (en) | Vaccine combinations | |
| GB201208957D0 (en) | sure- safe sleeve | |
| GB201217321D0 (en) | Vaccine | |
| GB201206169D0 (en) | Vaccine | |
| GB201205599D0 (en) | Vaccine | |
| GB201108256D0 (en) | Vaccine | |
| GB201121647D0 (en) | Vaccine | |
| GB201108982D0 (en) | Vaccines | |
| GB201108986D0 (en) | Vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |